FDA Form 2253 is an important part of promotional compliance for pharmaceutical companies in the United States. It helps drug sponsors submit applicable advertising and promotional labeling materials to the U.S. Food and Drug Administration (FDA). For pharma marketers, understanding this form is essential when planning product launches, preparing promotional campaigns, and managing regulatory submissions.
However, completing the form is only one part of the process. Teams must also confirm that promotional content aligns with the product’s current prescribing information, maintain accurate submission records, and coordinate reviews across marketing, medical, legal, and regulatory teams.
This guide explains FDA Form 2253, its purpose, submission timing, required information, and common mistakes. It also shares practical ways to improve launch compliance and manage promotional materials across digital and traditional channels.
What Is FDA Form 2253?
FDA Form 2253, officially called the Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use, is a form used to transmit applicable promotional materials to the FDA. It helps the agency identify the product, applicant, and advertising or labeling materials included in a submission.
Under 21 CFR 314.81(b)(3)(i), applicants generally must submit applicable prescription drug advertisements and promotional labeling at the time of initial publication or dissemination. Requirements for biological products are also addressed under 21 CFR 601.12(f)(4). The FDA explains these requirements in its OPDP Frequently Asked Questions.
For marketing teams, FDA Form 2253 connects an approved product’s promotional activity with the regulatory records associated with that product. It is not a general marketing approval application, nor does submitting the form mean that the FDA has approved every claim or advertisement.
Why Is FDA Form 2253 Important for Pharma Marketers?
Pharmaceutical promotion carries responsibilities that ordinary consumer advertising does not. Promotional claims must remain truthful and non-misleading, align with applicable requirements, and present important risk information appropriately.
FDA Form 2253 supports the submission and documentation process. When teams manage it correctly, they can reduce administrative errors, improve coordination, and maintain a clearer record of promotional activity.
It is particularly important during product launches, when teams may prepare sales aids, product brochures, digital advertisements, websites, email campaigns, and other promotional materials at the same time. Each asset needs appropriate review, classification, and documentation.
A consistent process also helps marketing and regulatory teams answer practical questions: Which version was used? When was it first published? Which product application does it relate to? Was the correct prescribing information included? Who is responsible for the submission?
These checks support stronger launch compliance and make later audits or internal reviews easier to manage.
When Must FDA Form 2253 Be Submitted?
For applicable prescription drug promotional materials, the general rule is to submit the materials at the time of initial publication or dissemination. This means that teams should plan submission dates alongside campaign release dates rather than treating documentation as an afterthought.
The exact process depends on the product, submission type, and applicable regulatory requirements. Certain products approved under the accelerated approval pathway have specific pre-submission requirements for promotional materials. FDA guidance explains that materials intended for use during the first 120 days after approval generally need to be submitted for review during the pre-approval period, unless the FDA provides different instructions. After that period, applicable materials generally must be submitted at least 30 days before initial publication or dissemination. Teams should confirm the conditions that apply to their product under FDA guidance on biologics advertising and promotional labeling and the relevant regulations.
The distinction between a routine final submission and a request for FDA feedback on draft material is important. Companies may voluntarily request advisory comments on draft promotional pieces before publication. That process is different from submitting final materials through FDA Form 2253.
FDA Form 2253 Submission Timing at a Glance
| Submission situation | General timing | Important consideration |
|---|---|---|
| Applicable final promotional materials | At initial publication or dissemination | Confirm the applicable requirements and include the required materials |
| Voluntary request for advisory comments | Before publication or dissemination | Follow FDA guidance for draft submissions |
| Certain accelerated approval launch materials | During the pre-approval review period | Confirm the specific product requirements |
| Certain accelerated approval materials after the first 120 days | Generally at least 30 days before initial publication or dissemination | Verify applicable regulatory conditions |
These are general descriptions, not a substitute for reviewing the current requirements for a specific product.
What Information Is Required on FDA Form 2253?
The form captures key details about the product, applicant, and promotional materials. Accurate information matters because errors can delay internal processing, create uncertainty, or lead to avoidable corrections.
The current FDA Form 2253 instructions explain the information required in each field. Teams should always check the latest form and instructions before preparing a submission.
| Form section | Information to prepare | Why it matters |
|---|---|---|
| Submission date | Date the form and accompanying materials are sent | Supports accurate submission records |
| Application information | Applicable application type and number | Connects the materials to the correct product application |
| Product details | Proprietary and established names | Identifies the drug or biological product |
| Labeling information | Date and identification number of current professional labeling | Helps ensure the submission refers to the correct labeling |
| Promotional material details | Material type, description, identification code, and audience | Makes each submitted item easier to identify |
| Publication or dissemination date | Date the material is first used or published | Documents the timing of promotional activity |
| Applicant or agent details | Contact information and responsible official | Establishes a contact for questions about the submission |
Teams should pay particular attention to the date fields. The form distinguishes the date the submission is sent from the initial publication or dissemination date for each promotional item. These dates serve different purposes and should not be treated as interchangeable.
The material listing also needs care. The FDA instructions state that each promotional item should be listed separately. Individual parts of promotional kits should be identified, and consumer-facing and professional-facing pieces should be handled according to the instructions.
Which Promotional Materials May Need Submission?
FDA Form 2253 is relevant to applicable advertising and promotional labeling for human prescription drugs and biological products. Examples can include print advertisements, brochures, sales aids, video advertisements, product websites, promotional emails, and social media content.
The exact requirements depend on the product and material. Do not assume that every communication mentioning a company or medicine is automatically promotional labeling. Similarly, do not assume that digital content is exempt simply because it appears online.
The FDA’s form instructions include material categories for social media, websites, internet video, electronic communications, sponsored links, and mobile technology. This makes classification important for modern campaigns that use multiple channels.
For example, a pharma marketing team preparing a product campaign might manage a healthcare professional sales aid, a patient brochure, a website update, and a social media advertisement. The team should identify each applicable item, confirm its regulatory status, and document it through the appropriate submission process.
A review checklist can help teams decide what to prepare:
Identify the product and its application number.
Confirm whether the item falls within the applicable submission requirements.
Record the audience, material type, description, and internal identification code.
Verify the initial publication or dissemination date.
Confirm the correct current professional labeling and supporting documentation.
Check the submission format and any product-specific requirements.
This process is a practical control, not a replacement for regulatory judgment.
How to Prepare and Submit FDA Form 2253
A well-organized submission process starts before a promotional asset reaches its final stage. When marketing teams wait until launch day to gather materials, they increase the risk of missing details or submitting the wrong version.
1. Identify the product and submission type
Start by confirming the product name, application type, application number, and any other details required by the form. If a promotional piece refers to more than one product, follow the FDA instructions for multiple-product submissions.
2. Confirm the final promotional material
Make sure the submitted asset matches the version approved through the company’s internal review process. The material description and internal ID should clearly identify the item. Keep a record of the approved version so the team can link it to the submission.
3. Check the current professional labeling
Compare promotional claims against the applicable product labeling. Confirm that the materials use the correct version and that any required labeling accompanies the submission. FDA instructions specify labeling details and supporting items for applicable submissions.
4. Record publication or dissemination dates
Coordinate with campaign owners to document when the material is first published or distributed. This date should align with the campaign record and the form. If a campaign has several assets with different launch dates, track the dates for each asset instead of using one general campaign date.
5. Follow the correct submission format
The FDA’s electronic submission guidance explains submission formats for promotional materials. Electronic submissions are required for submissions within the scope of the applicable electronic-submission requirements. Teams should confirm the current technical specifications and any exceptions that apply rather than relying on an outdated workflow.
6. Retain the submission record
Keep the final promotional asset, completed form, labeling, submission confirmation, and related review records together. A central record helps teams respond to questions and confirm that the published item matches the version documented in the submission.
Common FDA Form 2253 Mistakes to Avoid
Many submission problems come from process gaps rather than a lack of effort. Clear ownership and a standard checklist can help teams catch issues before sending materials.
One common mistake is using outdated product labeling. A submission may contain the correct promotional item but still require correction if the labeling details are not current. Teams should verify the approved version before each applicable submission.
Another problem is treating a campaign as one asset when it contains multiple materials. A product launch might include a brochure, social media post, email, and video. Each item should be identified and handled according to the applicable requirements.
Incorrect dates can also weaken the submission record. The initial publication or dissemination date should reflect when the relevant promotional item is first used, not when the team began designing it or received internal approval.
Finally, teams should not assume that submission equals FDA approval. The FDA explains that companies can request advisory comments on draft promotional content, but this is different from a routine final submission. Companies remain responsible for ensuring that their promotional materials comply with applicable law and regulations.
Best Practices for Managing FDA Form 2253 Across Teams
A reliable process gives marketing, medical, legal, and regulatory teams clear roles. Marketing can own campaign details and asset identifiers, while regulatory teams confirm submission requirements and manage the regulatory record. Medical and legal reviewers can assess claims and supporting evidence within the company’s review framework.
In addition, teams should use a single source of truth for labeling, approved content, version numbers, and submission dates. A shared tracker or compliant content platform can reduce duplicate work and make status checks easier.
Automation can also help with routine tasks such as routing assets for review, recording approvals, and reminding owners about required fields. However, automation should not replace human review of product claims, risk information, or regulatory decisions. A final quality check remains essential.
A practical workflow looks like this:
| Stage | Core activity | Expected control |
|---|---|---|
| Planning | Identify product, channels, and assets | Clear ownership and submission plan |
| Review | Assess claims and supporting evidence | Documented medical, legal, and regulatory review |
| Finalization | Confirm labeling, version, and material details | Approved final asset and complete form data |
| Submission | Submit according to applicable FDA requirements | Correct format and submission confirmation |
| Recordkeeping | Store final assets and submission evidence | Searchable record and clear audit trail |
These controls help teams manage promotional materials more consistently, especially when several campaigns run at once. They can also support stronger governance across digital marketing programs.
Conclusion
FDA Form 2253 plays an important role in managing applicable pharmaceutical advertising and promotional labeling submissions. By understanding submission timing, preparing accurate form details, checking current labeling, and maintaining clear records, pharma teams can improve their promotional compliance processes.
A well-defined workflow also helps marketing, medical, legal, and regulatory teams coordinate more effectively. As pharmaceutical campaigns expand across websites, email, video, and social media, consistent asset tracking and review become even more valuable.
Ultimately, FDA Form 2253 should be part of a broader compliance process that supports accurate documentation, responsible promotion, and better campaign governance. Teams should verify current FDA guidance and consult their regulatory experts when requirements are unclear.
Connect With MarketBeam
MarketBeam helps regulated organizations manage social media workflows, content approvals, and governance across enterprise marketing teams. Strong processes can help teams coordinate campaigns while maintaining the oversight required for regulated communications.
Sales: sales@marketbeam.io Tech Support: support@marketbeam.io
Frequently Asked Questions
1. What is FDA Form 2253 used for?
FDA Form 2253 is used to transmit applicable advertising and promotional labeling materials for human prescription drugs and biological products to the FDA. It identifies the product, applicant, and promotional materials included in the submission.
2. When should FDA Form 2253 be submitted?
Applicable final promotional materials generally must be submitted at the time of initial publication or dissemination. Special requirements may apply to certain products, including products approved under the accelerated approval pathway.
3. Does submitting FDA Form 2253 mean the FDA has approved an advertisement?
No. A routine final submission does not mean the FDA has approved the advertisement. Companies remain responsible for ensuring that promotional materials meet applicable legal and regulatory requirements.
4. Which materials may require FDA Form 2253?
Applicable materials may include print advertisements, brochures, sales aids, promotional emails, websites, videos, and social media content. Requirements depend on the product, material, and applicable regulations.
5. What information is required on FDA Form 2253?
The form requests application and product details, current labeling information, promotional material descriptions, material types, initial publication or dissemination dates, and applicant or responsible official details.
6. Can pharmaceutical companies submit FDA Form 2253 electronically?
Yes. Electronic submissions are required for materials within the scope of applicable FDA electronic-submission requirements. Teams should consult the FDA’s current OPDP electronic submission resources to confirm the correct format and process.
